Skip to main content

Faster-acting insulin aspart

Injection pen

09-22-2021 | Faster-acting insulin aspart | News

Real-world backing for glycemic benefits of faster aspart

Switching to fast-acting insulin aspart is associated with an increased time in range and reduced glycemic variability, show data from a real-world observational study.

12-01-2020 | Faster-acting insulin aspart | News

Real-world data support improved glycemic control with faster aspart

Switching to fast-acting insulin aspart significantly improves glycemic control and time in glucose target range in people with type 1 diabetes using continuous glucose monitoring, data from the real-world GoBolus study show.

09-25-2020 | EASD 2020 | Conference coverage | News

Fully closed-loop insulin delivery edges closer with pramlintide–faster aspart system

A fully automated dual-hormone delivery system with pramlintide and faster-acting insulin aspart delivers overall glycemic control that is nearly as good as that achieved with a hybrid closed-loop system with the insulin only, report researchers at the virtual 56th EASD Annual Meeting.

03-31-2020 | Faster-acting insulin aspart | News

Onset 9: Faster aspart may have advantages over insulin aspart in advanced type 2 diabetes

Fast-acting insulin aspart results in equal, but not better, glycemic control to insulin aspart in adults whose long-standing type 2 diabetes is not adequately controlled with a basal–bolus regimen, a trial conducted in 17 countries suggests.

12-13-2018 | Faster-acting insulin aspart | News

Fast-acting insulin aspart efficacy confirmed in CSII setting

Fast-acting insulin aspart is as effective as insulin aspart for glucose control when used for continuous subcutaneous insulin infusion in adults with type 1 diabetes, results of the onset 5 study show.

02-10-2017 | Faster-acting insulin aspart | News

Ultrafast-acting insulin effective in children

The pharmacodynamics of faster-acting insulin aspart in children are similar to those in adults, suggesting its ability to improve postprandial glycemic control in children with type 1 diabetes, say researchers.